Opyl (ASX:OPL) has announced a new agreement with clinical research organisation and strategic planning and commercialisation advisory firm Biointelect.
Biointelect will leverage Opyl's TrialKey to optimise clinical trial outcomes and strategies by analysing extensive clinical datasets.
The six-month agreement includes a service fee, with Biointelect engaging Opyl for design services at $5,000 per trial.
BioIntelect will utilise the TrialKey platform to access detailed trial design insights, success rate predictions, and strategic recommendations.
Opyl executive chairman Saurabh Jain said, "We are excited to partner with Biointelect, a key player in life sciences consulting. By deploying TrialKey’s industry-leading data-driven analytics, we aim to transform clinical trial designs, ultimately boosting the probability of success for Biointelect's clients."
Jacqui Wade, the director of clinical affairs and director services at Biointelect, added, "Integrating Opyl’s TrialKey platform into our clinical trial design services brings significant value to our clients. With over 30 years in the pharmaceutical and biotech industry, I see the critical role that data-driven insights play in optimising trial outcomes. TrialKey’s capability to analyse large datasets and provide reliable biostatistical validation is exactly what our clients need to drive product development forward."
